Semaglutide vs Tirzepatide vs Retatrutide in Research

Semaglutide vs Tirzepatide vs Retatrutide in Research

Research use only

This article is for scientific context. Semaglutide, Tirzepatide and Retatrutide sold on this site are research-grade chemical reagents. They are not medicines, not TGA-approved for supply as therapeutic goods in this form, and not for human consumption, therapeutic use, diagnostic use or veterinary use.


In brief

These three synthetic peptides are used in laboratory research on incretin and glucagon receptor signalling. They differ mainly in which receptors they engage and in the structural features that produce that profile.

PeptideReceptor profileLengthMolecular weight (approx.)CAS
SemaglutideGLP-1 receptor agonist31 aa4114 g/mol910463-68-2
TirzepatideDual GIP + GLP-1 agonist39 aa4813.5 g/mol2023788-19-2
RetatrutideTriple GIP + GLP-1 + glucagon agonist39 aa4731 g/mol2381089-83-2

A key paper describing the design of the triple agonist (Retatrutide, LY3437943) is Coskun et al., Cell Metabolism (2022):
LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss.


Semaglutide — single GLP-1 receptor agonist

Semaglutide is a 31-amino-acid peptide built on a modified GLP-1(7-37) backbone. It is used in research as a selective GLP-1 receptor (GLP-1R) agonist.

Key structural features:

  • Alanine at position 8 replaced by α-aminoisobutyric acid (Aib) for proteolytic stability
  • Lysine at position 34 replaced by arginine
  • Lysine at position 26 acylated with a C18 fatty diacid via a γ-glutamate + AEEA linker (albumin-binding modification)

Formula: C₁₈₇H₂₉₁N₄₅O₅₉
Typical research use: GLP-1R pharmacology, cAMP signalling assays, comparison against dual or triple agonists in the same panel.

PubChem record: CID 56843331.


Tirzepatide — dual GIP / GLP-1 agonist

Tirzepatide (LY3298176) is a 39-amino-acid peptide designed on a GIP backbone with modifications that confer balanced activity at both the GIP receptor (GIPR) and GLP-1R.

Key structural features:

  • Two Aib residues (positions 2 and 13)
  • C-terminal amide
  • Lysine at position 20 conjugated to a C20 fatty diacid via a hydrophilic linker

Formula: C₂₂₅H₃₄₈N₄₈O₆₈
Typical research use: Dual incretin receptor studies, head-to-head comparison with selective GLP-1R agonists, investigation of synergistic GIP + GLP-1 signalling in cellular and animal models.


Retatrutide — triple GIP / GLP-1 / glucagon agonist

Retatrutide (LY3437943) is a 39-amino-acid peptide that adds glucagon receptor (GCGR) activity to the dual GIP/GLP-1 profile. It is the first widely studied balanced triple agonist of this type.

Key structural features:

  • Aib at positions 2 and 20
  • α-methyl-leucine at position 13
  • Lipidation at Lys17 with a C20 fatty diacid via linker
  • C-terminal amide

Formula: C₂₂₁H₃₄₂N₄₆O₆₈
Typical research use: Triple-receptor pharmacology panels, studies of energy expenditure pathways linked to GCGR, comparative work against dual agonists.

The design and early characterisation are described in the Coskun et al. Cell Metabolism paper.


Side-by-side research comparison

FeatureSemaglutideTirzepatideRetatrutide
Primary receptorsGLP-1RGIPR + GLP-1RGIPR + GLP-1R + GCGR
Agonist classSingleDualTriple
Length31 aa39 aa39 aa
LipidationC18 diacid at Lys26C20 diacid at Lys20C20 diacid at Lys17
Non-coded residuesAib (pos. 8)Aib (pos. 2, 13)Aib (pos. 2, 20) + α-MeLeu (pos. 13)
C-terminusFree acidAmideAmide
Typical lab contextSelective GLP-1R referenceDual incretin referenceTriple agonist reference

Researchers choose among them according to the receptor set required for the assay. A selective GLP-1R experiment uses Semaglutide. A dual GIP/GLP-1 panel uses Tirzepatide. A triple panel that includes GCGR uses Retatrutide.


Laboratory applications

These peptides appear in:

  • Receptor pharmacology and cAMP / calcium signalling assays
  • Comparative studies of single vs dual vs triple agonism
  • Cellular models of glucose handling and insulin signalling
  • Animal metabolic models (institutional ethics approval required)
  • Structural and binding studies of the respective GPCRs

They are supplied as lyophilised research reagents for reconstitution according to the experimental protocol. They are not pharmaceutical-grade injectable medicines.


Quality and documentation notes

For reproducible work, confirm each batch against:

  • Expected sequence and modifications
  • HPLC purity (typically ≥98% for research-grade material)
  • Mass-spectrometric identity matching the stated molecular weight
  • Batch-specific Certificate of Analysis

HPLC purity is not the same as net peptide content. Salt form and residual moisture affect the actual peptide mass in the vial. Use the CoA for concentration-critical work.


Regulatory note (Australia)

Unapproved peptide products are regulated as therapeutic goods if supplied or promoted for human use. A “research use only” statement does not make human supply lawful. These materials are sold only for laboratory research, with Australia-only shipping, to buyers who confirm research intent.


Sources